Peer-Reviewed Publication Highlights First-of-its-Kind Continuous Monitoring Platform for Intensive Care Units

High Acceptance of Advanced Healthcare Equipment Promoting Growth of a-Si X-ray Flat Panel Detectors | Fact.MR’s Medtech Analysis

Big data and analytics will drive patient outcomes in a big way, and the coming years will witness a growing emphasis on healthcare service providers in the business of gathering and processing patient health data.

KA Imaging Makes Distribution Deal with Malaysia Based BeyMed

BeyMed is an emerging medical solutions company with a great potential,” said Amol Karnick, President and CEO of KA Imaging. Raises a $3M Series a Round to Scale Up Its Health Tech Platform in the MENA

The UK-based, MENA focused, startup closed $3M in its Series A round of funding led by MEVP with the participation of SOSF, IM capital and returning investors iSME, Cedar Mundi Ventures and IFA capital.

OptiScan Biomedical Corporation announced the online publication of two peer-reviewed papers highlighting key benefits delivered by the company’s OptiScanner continuous monitoring platform for intensive care units.  The publications provide further support for the ability of the OptiScanner to facilitate enhanced glucose level control in critically ill patients, offering key advantages over traditional, non-automated, labor-intensive glucose monitoring methods.

The OptiScanner is the first-of-its-kind automated, bedside blood monitor for use in the intensive care unit.  The OptiScanner 5000 measures glucose values directly from a micro-sample of blood using spectroscopy technology without the need for calibration, providing trending glucose data with updates every 15 minutes to help manage patients’ glucose levels within a target range.

One paper, entitled “Fifteen minute frequency of glucose measurements and the use of threshold alarms: Impact on mitigating dysglycemia in critically ill patients,” was published online in the Journal of Diabetes Science and Technology.  The paper contained results from a sub-analysis of the company’s previously completed 200-patient, U.S. multi-center MANAGE IDE study, which evaluated the performance of the OptiScanner 5000 while keeping treating clinicians blinded to the platform’s output.  This sub-analysis, which was conducted by an independent group of clinical advisors, was intended to assess the potential of unblinded use of the OptiScanner platform to prevent cases of dysglycemia in the ICU.  Findings of the sub-analysis demonstrated that 51.5% of patients exhibited at least one episode of dysglycemia.  The independent group of clinical advisors believe that 97.1% of the 103 dysglycemia episodes that were experienced in the MANAGE IDE study would likely have been averted with unblinded use of the OptiScanner and its automated glucose measurements every fifteen minutes.

“The conclusions of the independent clinical advisors strongly suggest that the OptiScanner has the potential to markedly improve the quality and safety of glucose control for critically ill patients in the ICU through automated and trending monitoring every 15 minutes,” stated the paper’s author, James S. Krinsley, MD, FCCM, FCCP, Director of Critical Care at Stamford Hospital in Stamford, CT., and Clinical Professor of Medicine, Columbia Vagelos College of Physicians and Surgeons.  “Optimal glucose control in these patients is difficult with traditional, non-automated technologies which require extensive resources, typically only measure every two to four hours and don’t provide the type of glucose level trending that allows for avoidance of dysglycemia.  In my experience, the OptiScanner platform is the first bedside system that offers the trending information that allows clinicians to act before glucose levels drift out of optimal range, and it does so while freeing up significant time for nurses to attend to other important activities.”

A second paper, entitled “Results of a Multi-Center Feasibility Study of an Automated Bedside Glucose Monitoring System in the Burn Intensive Care Setting (LOFT Study),” was published online in the Journal of Burn Care & Research.  The LOFT Study represents the 13th clinical study conducted on the company’s OptiScanner platform, with its findings further expanding clinical support for the role the technology can play in enhancing the care of critically ill patients.   Study results demonstrated the ability of the OptiScanner to perform reliable and accurate plasma glucose measurements for patients in the burn intensive care setting.  These findings highlight the ability of the OptiScanner to automate glucose monitoring as a means to potentially improving clinical outcomes in this unique critical care burn population.

“Our results demonstrate that the OptiScanner is able to maintain its accuracy and reliability as a bedside glucose assay, even in this particularly difficult population of critically ill burn patients.  We are excited to be part of OptiScan’s efforts to apply their emerging technology to these particularly high-risk patients,” said the paper’s author, Joshua Carson, MD, FACS, Assistant Professor, Division of Acute Care Surgery and Burns and Associate Director, UF Shands Burn Center, University of Florida Department of Surgery.

“We are pleased to have these important study results featured in such highly-regarded peer-reviewed journals as Journal of Diabetes Science and Technology and Journal of Burn Care & Research.  These published findings support the broad utility of the OptiScanner platform to assist clinicians in maintaining target plasma glucose levels in critically ill patients in the burn ICU, as well as the broad ICU setting,” said Cary G. Vance, chief executive officer of OptiScan.  “We are committed to transforming the treatment of critically ill patients through automated bedside monitoring of glucose and other key analytes and will continue to conduct and publish studies of this type which offer rigorous scientific support for the benefits of the OptiScanner platform.”



Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles